CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention.

ABSTRACT: Cutaneous T-Cell Lymphoma (CTCL) is a non-Hodgkin's lymphoma involving malignant skin-homing T-cells, characterized by variable severity and limited treatment options. Our study shows that patient samples and derived cell lines express CD38 on CTCL cells, and αCD38 antibodies effectively target CD38 in a mouse model. In vivo αCD38 antibody treatment led to the loss of CD38 expression in residual tumor cells, highlighting the need for innovative strategies to improve CTCL outcomes despite the CD38 loss in residual tumor cells. To investigate the role of CD38 in CTCL pathology, we used CRISPR-Cas9 to create CD38-deficient (CD38^KO) CTCL cells. These CD38^KO cells showed higher expression of oncogenes B-catenin, TCF7, and BCL6, along with reduced migration. Elevated NAD+ l

SUBMITTER: Isabelle C 

PROVIDER: S-EPMC12055602 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature